Literature DB >> 6467127

Mononuclear phagocyte function in head and neck cancer. Chemotactic responsiveness of blood monocytes in correlation between histologic grade of the tumor and infiltration of these cells into the tumor area.

F A Balm, H A Drexhage, M von Blomberg, E F Weltevreden, R W Veldhuizen, R Mullink, G B Snow.   

Abstract

The chemotactic responsiveness of peripheral monocytes and the acid-phosphatase activity of tumor-infiltrating macrophages, as well as the ultrastructural appearance, were studied in 40 patients with squamous cell carcinoma of the head and neck. The chemotactic responsiveness was found to be decreased in carcinoma patients, and this value appeared to be positively correlated in individual patients with the number of tumor-infiltrating macrophages, as well as with the histologic grade of the tumor. Patients with poorly differentiated malignancies showed impaired monocyte chemotactic responsiveness and low numbers of tumor-infiltrating macrophages. Macrophages present in the parenchyma of the tumor showed a weak and diffuse pattern of acid phosphatase activity. The acid phosphatase activity of stromal macrophages was much stronger and distributed in foci. Electron microscopic examination of the parenchymal macrophages revealed low numbers of lysosomes and the presence of tumor cell debris in the cytoplasm of the cell, without any sign of a surrounding phagosomal membrane. Together with the weak cytochemical reactivity, this probably indicates the poor functional state of the phagocyte when infiltrated in the parenchyma of the tumor. Low molecular weight factors derived from the tumor are known to decrease chemotactic responsiveness of peripheral monocytes. The poor functional state of the macrophages infiltrated within tumor parenchyma might be explained by assuming that a high concentration of such factors in the near vicinity of malignant cells causes toxic effects in macrophages.

Entities:  

Mesh:

Year:  1984        PMID: 6467127     DOI: 10.1002/1097-0142(19840915)54:6<1010::aid-cncr2820540613>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Defective monocyte chemotaxis in patients with epidermoid tumors of the head and neck.

Authors:  A Güngör; S Yetgin; B Sözeri
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

2.  In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells.

Authors:  J Hald; N Rasmussen; M H Claesson
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

3.  Immunosuppressive retroviral-related factors in sera of patients with head and neck cancer.

Authors:  I B Tan; A J Balm; G B Snow; H A Drexhage
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

4.  Macrophage and dendritic cell infiltration in head and neck squamous-cell carcinoma; an immunohistochemical study.

Authors:  J D Kerrebijn; A J Balm; P P Knegt; C A Meeuwis; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

5.  In vivo effects of thymostimulin treatment on monocyte polarization, dendritic cell clustering and serum p15E-like trans-membrane factors in operable head and neck squamous cell carcinoma patients.

Authors:  J D Kerrebijn; P J Simons; M Tas; A J Balm; H A Drexhage
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

6.  Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer.

Authors:  P J Simons; R A Oostendorp; M P Tas; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

7.  Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones.

Authors:  M P Tas; P J Simons; F J Balm; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.